Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer

Breast Cancer Research and Treatment

Volumn 174, Issue 2, 2019, Pages 443-452

  Patel, Dilan A ^a,b   Xi, Jing ^a,c   Luo, Jingqin ^a   Hassan, Bilal ^a   Thomas, Shana ^a   Ma, Cynthia X ^a   Campian, Jian L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c St Lukes's Hospital   (United States)

Author keywords

Neutrophil to lymphocyte ratio (NLR); Overall survival (OS); Triple negative breast cancer (TNBC)

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEOADJUVANT CHEMOTHERAPY; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; BLOOD; CHEMORADIOTHERAPY; CYTOLOGY; DRUG EFFECT; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; NEUTROPHIL; RADIATION RESPONSE; TREATMENT OUTCOME;

ADULT; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOPENIA; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; NEUTROPHILS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85059645118     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-018-05106-7     Document Type: Article

References (42)

1. Female Breast Cancer - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/breast.html. Accessed 30 April 2018
2. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948
3. Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22(11):1233–1243
4. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S (2011) Triple negative breast cancer: prognostic factors and survival. Radiol Oncol 45(1):46–52
5. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674–690
6. Campian JL, Ye X, Brock M, Grossman SA (2013) Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 31(3):183–188
7. Grossman SA et al (2015) Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw 13(10):1225–1231
8. Ray-Coquard I et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69(13):5383–5391
9. Shin H, Kim J, Kim HJ (2015) Neutrophil lymphocyte ratio (NLR) change after systemic treatment as a predictive factor of cancer specific survival in stage IV breast cancer. J Clin Oncol 33(28_suppl):29–29
10. Ethier J-L, Desautels D, Templeton A, Shah PS, Amir E (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19:2
11. Templeton AJ et al. (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 10.1093/jnci/dju124
12. Pistelli M et al (2015) Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer 15(1):195
13. Hong J et al (2016) Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. Tumor Biol 37(3):4135–4142
14. Rimando J, Campbell J, Kim JH, Tang S-C, Kim S (2016) The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer. Front Oncol 6:81
15. Dirican A et al (2015) Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol 20(1):70–81
16. Azab B et al (2013) Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30(1):432
17. Koh C-H et al (2015) Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 113(1):150–158
18. Fu P et al. (2014) Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther 7:1743
19. Asano Y et al (2016) Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol 23(4):1104–1110
20. Forget P, Bentin C, Machiels J-P, Berliere M, Coulie PG, De Kock M (2014) Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 113:i82–i87
21. Nakano K, Hosoda M, Yamamoto M, Yamashita H (2014) Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer. Anticancer Res 34(7):3819–3824
22. Koh YW, Lee HJ, Ahn J-H, Lee JW, Gong G (2014) Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biol 35(10):9823–9830
23. Azab B et al (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19(1):217–224
24. Aaltomaa S et al (1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A(4–5):859–864
25. Desmedt C et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16):5158–5165
26. Schmidt M et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405–5413
27. Gu-Trantien C et al (2013) CD4 + follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123(7):2873–2892
28. Verma R et al (2016) Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 18(1):10
29. Orditura M et al (2016) Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open 1(2):e000038
30. Ayala F, de la Peña et al (2017) 283PNeutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer. Ann Oncol. 10.1093/annonc/mdx365.046
31. Walker PR, Hildebrand JR (2016) Pretreatment neutrophil to lymphocyte ratio (NLR) in patients with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. J Clin Oncol 34(15_suppl):e12570–e12570
32. Jerzak K, Zhu S, Nofech-Mozes S, Pond G, Warner E (2018) Abstract P3-08-12: prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC). Cancer Res 78(4 Supplement):P3-08–P3-12
33. Noh H, Eomm M, Han A (2013) Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer 16(1):55–59
34. Mazouz A et al (2015) Prognostic value of pretreatment neutrophil lymphocyte ratio in metastatic breast cancer. J Clin Oncol 33(15_suppl):e11500–e11500
35. Chae S et al (2018) Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr Oncol 25(2):e113–e119
36. Yersal Ö et al (2017) Neutrophil/lymphocyte and platelet/lymphocyte ratios are not different among breast cancer subtypes. Asian Pac J Cancer Prev 18(8):2227–2231
37. Pearson A et al (2016) Prognostic utility of tumour infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) in early-stage triple negative breast cancer (TNBC). J Clin Oncol 34(15_suppl):1075
38. Wu ES et al (2016) Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol 140(1):76–82
39. Dua I, Tan AR (2017) Immunotherapy for triple-negative breast cancer: a focus on immune checkpoint inhibitors. Am J Hematol/Oncol 13(4):20–27
40. Kwa MJ, Adams S (2018) Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer 124(10):2086–2103
41. Campian JL et al (2014) Feasibility of lymphocyte harvesting and reinfusion in patients with newly diagnosed high-grade gliomas. J Clin Oncol 32(15_suppl):2094
42. Romee R et al (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515